Proteon Therapeutics Inc (PRTO) was Initiated by Robert W. Baird to “Outperform” and the brokerage firm has set the Price Target at $20. Robert W. Baird advised their investors in a research report released on Apr 14, 2016.
Many Wall Street Analysts have commented on Proteon Therapeutics Inc. Shares were Reiterated by Stifel on Mar 15, 2016 to “Buy” and Lowered the Price Target to $ 19 from a previous price target of $20 .
Proteon Therapeutics Inc closed down -0.22 points or -2.63% at $8.14 with 19,314 shares getting traded on Monday. Post opening the session at $8.46, the shares hit an intraday low of $8.06 and an intraday high of $9.2499 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jan 5, 2016, Timothy P Noyes (President and CEO) sold 5,000 shares at $13.88 per share price. According to the SEC, on Jul 8, 2015, Daniel Philip Gottlieb (VP Marketing & Bus Development) sold 1,965 shares at $16.86 per share price.
Proteon Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is primarily involved in research and development activities. The Company’s product candidate PRT-201 is a recombinant human elastase that it is developing to reduce vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of PRT-201 in patients undergoing creation of an arteriovenous fistula (AVF). It initiated the first of two Phase III trials for PRT-201 in radiocephalic AVFs.